|Bid||356.85 x 0|
|Ask||357.95 x 0|
|Day's range||354.15 - 371.15|
|52-week range||332.00 - 532.40|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||697.00|
XELPROSTM 0.005% for topical ophthalmic use is the first and only benzalkonium chloride-free form of latanoprost
For Sun Pharma Advanced Research Company Limited’s (NSEI:SPARC) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important.Read More...
In this commentary, I will examine Sun Pharma Advanced Research Company Limited’s (NSEI:SPARC) latest earnings update (31 March 2018) and compare these figures against its performance over the past coupleRead More...